JP2011503191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503191A5 JP2011503191A5 JP2010534132A JP2010534132A JP2011503191A5 JP 2011503191 A5 JP2011503191 A5 JP 2011503191A5 JP 2010534132 A JP2010534132 A JP 2010534132A JP 2010534132 A JP2010534132 A JP 2010534132A JP 2011503191 A5 JP2011503191 A5 JP 2011503191A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound according
- aliphatic
- acute
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000002193 Pain Diseases 0.000 claims description 65
- 150000001875 compounds Chemical class 0.000 claims description 49
- 125000001931 aliphatic group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 18
- 230000001154 acute effect Effects 0.000 claims description 16
- 125000001475 halogen functional group Chemical group 0.000 claims description 16
- 208000004296 neuralgia Diseases 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 11
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 230000002981 neuropathic effect Effects 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 6
- 208000008930 Low Back Pain Diseases 0.000 claims description 6
- 206010026749 Mania Diseases 0.000 claims description 6
- 208000000003 Breakthrough pain Diseases 0.000 claims description 5
- 208000006561 Cluster Headache Diseases 0.000 claims description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 5
- 208000004404 Intractable Pain Diseases 0.000 claims description 5
- 206010028836 Neck pain Diseases 0.000 claims description 5
- 208000004550 Postoperative Pain Diseases 0.000 claims description 5
- 208000005298 acute pain Diseases 0.000 claims description 5
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- -1 C3-C8 cycloaliphatic Chemical group 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 150000004867 thiadiazoles Chemical group 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000006820 Arthralgia Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000008035 Back Pain Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 206010021639 Incontinence Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 208000005198 spinal stenosis Diseases 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 206010011796 Cystitis interstitial Diseases 0.000 claims description 2
- 206010016059 Facial pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010019909 Hernia Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 206010033425 Pain in extremity Diseases 0.000 claims description 2
- 206010033557 Palpitations Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims description 2
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims description 2
- 208000003243 intestinal obstruction Diseases 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010059604 Radicular pain Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98749007P | 2007-11-13 | 2007-11-13 | |
| PCT/US2008/083173 WO2009064752A2 (en) | 2007-11-13 | 2008-11-12 | Heterocyclic derivatives as modulators of ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503191A JP2011503191A (ja) | 2011-01-27 |
| JP2011503191A5 true JP2011503191A5 (enExample) | 2012-12-20 |
Family
ID=40298764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534132A Withdrawn JP2011503191A (ja) | 2007-11-13 | 2008-11-12 | イオンチャネルのモジュレーターとしての複素環誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8097636B2 (enExample) |
| EP (1) | EP2220080B1 (enExample) |
| JP (1) | JP2011503191A (enExample) |
| KR (1) | KR20100101601A (enExample) |
| CN (1) | CN101910166A (enExample) |
| AT (1) | ATE540036T1 (enExample) |
| AU (1) | AU2008321142A1 (enExample) |
| CA (1) | CA2705547A1 (enExample) |
| ES (1) | ES2377172T3 (enExample) |
| IL (1) | IL205696A0 (enExample) |
| MX (1) | MX2010005307A (enExample) |
| NZ (1) | NZ585729A (enExample) |
| RU (1) | RU2010123876A (enExample) |
| WO (1) | WO2009064752A2 (enExample) |
| ZA (1) | ZA201003352B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| EP1888558B1 (en) * | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| ZA200802977B (en) * | 2005-09-09 | 2009-08-26 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| EP1948597A1 (en) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| CN102036985A (zh) | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| EP2307412A2 (en) * | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2013109521A1 (en) * | 2012-01-16 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Pyran-spirocyclic piperidine amides as modulators of ion channels |
| CN106045908B (zh) * | 2016-06-14 | 2018-09-28 | 郑州轻工业学院 | 一种新型化合物6,7-二溴-1,2,3,4-四氢异喹啉及其制备方法 |
| KR20200030584A (ko) | 2017-07-21 | 2020-03-20 | 앤타바이오 에스에이에스 | 화합물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH666623A5 (de) * | 1985-05-17 | 1988-08-15 | Idc Chemie Ag | Vorrichtung zur behandlung von brandwunden oder verbruehungen. |
| KR20060073930A (ko) * | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| CN101218235A (zh) * | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| EP1888558B1 (en) * | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| WO2006133459A1 (en) * | 2005-06-09 | 2006-12-14 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
| ZA200802977B (en) * | 2005-09-09 | 2009-08-26 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| US7683083B2 (en) * | 2005-10-12 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| EP1948597A1 (en) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| WO2007075895A2 (en) * | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CA2687764A1 (en) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| CN102036985A (zh) * | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| EP2307412A2 (en) * | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
-
2008
- 2008-11-12 AU AU2008321142A patent/AU2008321142A1/en not_active Abandoned
- 2008-11-12 CA CA2705547A patent/CA2705547A1/en not_active Abandoned
- 2008-11-12 RU RU2010123876/04A patent/RU2010123876A/ru not_active Application Discontinuation
- 2008-11-12 JP JP2010534132A patent/JP2011503191A/ja not_active Withdrawn
- 2008-11-12 CN CN2008801223353A patent/CN101910166A/zh active Pending
- 2008-11-12 MX MX2010005307A patent/MX2010005307A/es active IP Right Grant
- 2008-11-12 NZ NZ585729A patent/NZ585729A/en not_active IP Right Cessation
- 2008-11-12 AT AT08848685T patent/ATE540036T1/de active
- 2008-11-12 US US12/269,109 patent/US8097636B2/en active Active
- 2008-11-12 EP EP08848685A patent/EP2220080B1/en not_active Not-in-force
- 2008-11-12 ES ES08848685T patent/ES2377172T3/es active Active
- 2008-11-12 WO PCT/US2008/083173 patent/WO2009064752A2/en not_active Ceased
- 2008-11-12 KR KR1020107012966A patent/KR20100101601A/ko not_active Withdrawn
-
2010
- 2010-05-11 IL IL205696A patent/IL205696A0/en unknown
- 2010-05-12 ZA ZA2010/03352A patent/ZA201003352B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503112A5 (enExample) | ||
| JP2011526919A5 (enExample) | ||
| JP2010528035A5 (enExample) | ||
| RU2010123876A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| RU2010123781A (ru) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли | |
| JP2010539244A5 (enExample) | ||
| RU2011103451A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2014508756A5 (enExample) | ||
| JP2011500598A5 (enExample) | ||
| RU2016104080A (ru) | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов | |
| CN1048985C (zh) | 作为5－ht1a拮抗剂的哌嗪衍生物 | |
| CN100369894C (zh) | 氧化氮合酶抑制剂磷酸盐 | |
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| JP2014508169A5 (enExample) | ||
| JPS60228477A (ja) | ２‐アルコキシ‐ｎ‐（１‐アザビシクロ［２，２，２］オクト‐３‐イル）ベンズアミド類およびチオベンズアミド類 | |
| JP2008531537A5 (enExample) | ||
| JP2018524342A5 (enExample) | ||
| JP2012530682A (ja) | （２ｓ）−（−）−ｎ−（６−クロロ−２，３−ジヒドロ−ベンゾ［１，４］ジオキシン−２−イルメチル）−スルファミドの結晶形態 | |
| EA020050B1 (ru) | Новые замещенные производные сульфамидов | |
| JP2011505356A5 (enExample) | ||
| RU2492163C9 (ru) | Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии | |
| JP2000505114A (ja) | ５―アミノ―２，４，６―トリヨード―１，３―ベンゼンジカルボン酸誘導体を製造する方法 | |
| JP2012512145A5 (enExample) | ||
| RU2012102671A (ru) | Новые фумаратные соли антагониста гистаминового рецептора н3 | |
| JP2007531750A5 (enExample) |